Rosa Mayelín Guerra Bretaña

Biocompatibility of wollastonite‐poly(N‐butyl‐2‐cyanoacrylate) composites

Wollastonite-poly(n-butyl-2-cyanoacrylate) composite (W-BCA) has been proposed to immobilize anatomically bone fragments in order to achieve an optimal healing process. The present study evaluated the in vitro and in vivo behavior of three types of fillers: powdered natural wollastonite (Wn), synthetic pseudowollastonite powder (Ws), and synthetic pseudowollastonite powder coated with 5% acetyl tributyl citrate (Wst). The Wst-BCA composite underwent a higher degradability in the real-time degradation test and a superior cytotoxic effect; whereas the Wn-BCA composite showed a higher degradability in the accelerated test with no cytotoxicity. The formation of an extracellular collagenous matrix deposit on its surface and the most favorable new bone formation on Wn-BCA indicate its potential for bone adhesive use in unstable orthopedic traumas.

Effectiveness and Therapeutic Safety Using Β-Tricalcium Phosphate in Oral Bone Defects

Aim: To determine the effectiveness and therapeutic safety with β-tricalcium phosphate (Biograft-G®) in oral bone defects. Methods: A Phase III, multicenter, uncontrolled clinical trial (Classification of medical devices), to assess the Biograft-G® Biomaterials Center, University of Havana was made. All the population of the clinical trial was choose from four Cuban provinces and 121 patients was the sample selected for the studies. All the patients gave their consent to participate. The patients included in the study were: ages between 18 and 75 years, both sexes that could be treated surgically. Patients with malignant neoplasms of any location, diabetic patients who were decompensated or difficult to control, immunosuppressed or immunosuppressed, and mentally retarded patients were excluded. Surgeries were performed in patients requiring dental extraction, alveolar ridge reconstruction, periodontal and periapical surgery. The main variable was a clinical and radiographic appearance, evaluated in four periods (7 days, 1, 3 and 6 months) and levels: Success and Failure. Results: An effectiveness of 97.5% for β-tricalcium phosphate (Biograft-G®) was demonstrated. In all the periods of clinical and radiographic evaluation of it showed gradually reabsorption similar to surrounding healthy tissue, until the complete degradation of the biomaterial. It was determined that adverse treatment (infection, delamination of the material, tenderness and pain) events behaved low. Conclusion: It was concluded high effectiveness and safety of treatment with Biograft-G® in complex oral surgery, with minimal and mild adverse events to treatment.